CY1122533T1 - Ανακινρα για χρηση στην αντιμετωπιση συνδρομου αποφρακτικης βρογχιολιτιδας - Google Patents
Ανακινρα για χρηση στην αντιμετωπιση συνδρομου αποφρακτικης βρογχιολιτιδαςInfo
- Publication number
- CY1122533T1 CY1122533T1 CY20201100044T CY201100044T CY1122533T1 CY 1122533 T1 CY1122533 T1 CY 1122533T1 CY 20201100044 T CY20201100044 T CY 20201100044T CY 201100044 T CY201100044 T CY 201100044T CY 1122533 T1 CY1122533 T1 CY 1122533T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pro
- inflammatory cytokine
- anakinra
- treatment
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
Abstract
Η παρούσα εφεύρεση εστιάζεται σε μεθόδους και συνθέσεις για αντιμετώπιση φλεγμονωδών διαταραχών των κατώτερων αεραγωγών, οι οποίες περιλαμβάνουν χορήγηση μιας αποτελεσματικής ποσότητας ενός παράγοντα, ο οποίος ρυθμίζει την έκφραση και/ή τη δραστικότητα μιας προφλεγμονώδους κυτοκίνης ή θραύσματος αυτής), κατά προτίμηση σε έναν άνθρωπο. Η προφλεγμονώδης κυτοκίνη η οποία μελετάται από την εφεύρεση περιλαμβάνει IL-1, IL-6, IL-8 και TNF-άλφα. Η παρούσα εφεύρεση περιγράφει ένα κυτίο το οποίο περιλαμβάνει μια συσκευή παροχής και μια φαρμακευτική σύνθεση για χορήγηση του παράγοντα. Η φαρμακευτική σύνθεση περιλαμβάνει τουλάχιστον έναν αναστολέα προφλεγμονώδους κυτοκίνης, προαιρετικά ένα ή περισσότερα επιπρόσθετα δραστικά συστατικά, και τουλάχιστον έναν φαρμακευτικώς δραστικό φορέα. Η συσκευή παροχής περιλαμβάνει περαιτέρω έναν εκνεφωτή, έναν εισπνευστήρα, έναν διανομέα σκόνης, μια ενδοπνευμονική συσκευή παραγωγής αερολύματος (aerosolizer) και μια υπο-μικροσκοπική συσκευή παραγωγής αερολύματος.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83676006P | 2006-08-10 | 2006-08-10 | |
US87838507P | 2007-01-04 | 2007-01-04 | |
US90702807P | 2007-03-16 | 2007-03-16 | |
PCT/US2007/017800 WO2008021237A1 (en) | 2006-08-10 | 2007-08-10 | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122533T1 true CY1122533T1 (el) | 2021-01-27 |
Family
ID=39082316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100044T CY1122533T1 (el) | 2006-08-10 | 2020-01-20 | Ανακινρα για χρηση στην αντιμετωπιση συνδρομου αποφρακτικης βρογχιολιτιδας |
Country Status (14)
Country | Link |
---|---|
US (5) | US8940683B2 (el) |
EP (2) | EP2068889B1 (el) |
JP (1) | JP2010500360A (el) |
AU (1) | AU2007284690A1 (el) |
CA (2) | CA3177366A1 (el) |
CY (1) | CY1122533T1 (el) |
DK (1) | DK2068889T3 (el) |
ES (1) | ES2766770T3 (el) |
HU (1) | HUE048024T2 (el) |
LT (1) | LT2068889T (el) |
PL (1) | PL2068889T3 (el) |
PT (1) | PT2068889T (el) |
SI (1) | SI2068889T1 (el) |
WO (1) | WO2008021237A1 (el) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
US9895444B2 (en) * | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
CA3177366A1 (en) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
CA2688433A1 (en) | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
US8551534B2 (en) * | 2007-10-10 | 2013-10-08 | Parion Sciences, Inc. | Inhaled hypertonic saline delivered by a heated nasal cannula |
EP2259774B1 (en) | 2008-02-27 | 2012-12-12 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
DK2297202T3 (en) | 2008-05-13 | 2016-03-21 | Novimmune Sa | ANTI-IL-6 / IL-6R ANTIBODIES AND PROCEDURES FOR USE THEREOF |
US20100074881A1 (en) * | 2008-07-11 | 2010-03-25 | Parion Sciences, Inc. | Multiple nebulizer systems |
CA2772084C (en) | 2009-08-27 | 2016-10-18 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
CA2838529C (en) | 2011-06-07 | 2020-03-24 | Parion Sciences, Inc. | Methods of treatment |
WO2013152044A1 (en) * | 2012-04-02 | 2013-10-10 | The Board Of Regents Of The University Of Texas System | Use of pc-nsaids to treat and/or prevent pulmonary inflammation |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US9878011B2 (en) * | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
AU2013388034B2 (en) | 2013-04-30 | 2019-08-15 | Vectura Inc. | Dry powder formulations and methods of use |
US9833474B2 (en) | 2013-11-26 | 2017-12-05 | Biomet Biologies, LLC | Methods of mediating macrophage phenotypes |
EP3194033B1 (en) * | 2014-09-19 | 2022-05-04 | Aerovu Technologies, Inc. | Spacer device with flow rate spirometer |
US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
CN115919780A (zh) | 2017-09-22 | 2023-04-07 | 维克图拉公司 | 含有硬脂酸镁的干粉组合物 |
CA3083953A1 (en) | 2017-12-11 | 2019-06-20 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
JP6941224B2 (ja) | 2018-02-06 | 2021-09-29 | イージス セラピューティクス,エルエルシー | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 |
WO2020021574A1 (en) * | 2018-07-27 | 2020-01-30 | Wockhardt Limited | Pharmaceutical compositions and methods |
US20220409627A1 (en) * | 2019-12-02 | 2022-12-29 | Altavant Sciences Gmbh | Treatment of lower airways disorders |
CA3178404A1 (en) * | 2020-05-21 | 2021-11-25 | Stephen A. Wring | An inhaled il-1 blockade treatment for respiratory tract immunopathology |
WO2022016068A1 (en) * | 2020-07-16 | 2022-01-20 | Tbd Pharma Llc | Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections |
WO2022051247A1 (en) * | 2020-09-01 | 2022-03-10 | Dianomi Therapeutics, Inc. | Methods for treating or preventing inflammatory events |
US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
US20220339099A1 (en) * | 2021-04-22 | 2022-10-27 | Altavant Sciences Gmbh | Compositions of interleukin-1 receptor antagonist |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US5851526A (en) | 1985-04-19 | 1998-12-22 | Ludwig Institute For Cancer Research | Methods of treating colon cancer utilizing tumor-specific antibodies |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
EP0288088B1 (en) | 1987-04-24 | 1994-03-09 | Teijin Limited | Detection of tumor necrosis factor; monoclonal antibody and kit |
US5306620A (en) | 1987-07-08 | 1994-04-26 | The Scripps Research Institute | Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation |
US5149780A (en) | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
CA2000048A1 (en) | 1988-10-03 | 1990-04-03 | Edward F. Plow | Peptides and antibodies that inhibit integrin-ligand bindin g |
US5360716A (en) | 1988-10-24 | 1994-11-01 | Otsuka Pharmaceutical Co., Ltd. | Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α |
US5223395A (en) | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5498694A (en) | 1989-05-25 | 1996-03-12 | La Jolla Cancer Research Foundation | Peptides of the cytoplasmic domain of integrin |
US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
DE10399036I1 (de) | 1989-08-07 | 2004-04-01 | Peptide Technology Ltd | Bindeligande für Tumornekrosisfaktor. |
US5644034A (en) | 1989-08-07 | 1997-07-01 | Peptide Technology Ltd. | Tumour necrosis factor binding ligands |
EP0417563B1 (de) | 1989-09-12 | 2000-07-05 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
US5262520A (en) | 1989-12-01 | 1993-11-16 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
US5196511A (en) | 1989-12-01 | 1993-03-23 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
DE4006269A1 (de) | 1990-02-28 | 1991-08-29 | Max Planck Gesellschaft | Antikoerper gegen den tumor-nekrosefaktor-rezeptor |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
US5830678A (en) | 1990-10-30 | 1998-11-03 | Fred Hutchinson Cancer Research Center | Method for identifying a target peptide that modulates the binding of epinectin ligand to integrin receptors |
US5994510A (en) | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
AU1235392A (en) | 1991-01-14 | 1992-08-17 | New York University | Cytokine-induced protein, tsg-14, dna coding therefor and uses thereof |
DE69219913T2 (de) | 1991-01-15 | 1997-09-11 | Bayer Ag | Ergänzung von Oberflächenrezeptoren |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
US5698195A (en) | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US5310874A (en) | 1991-05-03 | 1994-05-10 | The Scripps Research Institute | Integrin α subunit cytoplasmic domain polypeptides and antibodies |
DE69230613T2 (de) | 1991-07-02 | 2000-12-28 | Inhale Inc | Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform |
US5334380A (en) | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
ATE175241T1 (de) | 1992-04-03 | 1999-01-15 | Genentech Inc | Antikörper gegen alpha v beta 3 integrin |
US5478725A (en) | 1992-06-12 | 1995-12-26 | University Of Pennsylvania | αv β3 integrin as a predictor of endometriosis |
AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
US5741488A (en) | 1992-10-08 | 1998-04-21 | The Kennedy Institute For Rheumatology | Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies |
SK279327B6 (sk) | 1992-10-19 | 1998-10-07 | Dura Pharmaceuticals | Zariadenie na vytváranie aerosolu z práškového lie |
US5705481A (en) | 1992-11-06 | 1998-01-06 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Cyclopeptides |
DE69414369T2 (de) | 1993-01-19 | 1999-05-27 | Glaxo Group Ltd | Aerosol-spender und verfahren zu seiner herstellung |
DE4310643A1 (de) | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
US5579578A (en) | 1993-10-27 | 1996-12-03 | Hayes Wheels International, Inc. | Method for producing a rim for a vechicle wheel |
IT1273790B (it) | 1994-02-18 | 1997-07-10 | Guidotti & C Spa Labor | Derivati eterociclici diazotati aventi attivita' aii antagonista |
US5523209A (en) | 1994-03-14 | 1996-06-04 | The Scripps Research Institute | Methods for identifying inhibitors of integrin activation |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5770565A (en) | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
DE4415310A1 (de) | 1994-04-30 | 1995-11-02 | Merck Patent Gmbh | Cyclopeptide |
NZ288997A (en) | 1994-06-24 | 1999-01-28 | Immunex Corp | Controlled release pharmaceutical formulation comprising polypeptide encapsulated in alginate |
US5579758A (en) | 1994-07-13 | 1996-12-03 | Century; Theodore J. | Sub-miniature aerosolizer with helical flow path formed by threaded insert |
DE69531187T2 (de) | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
US5513630A (en) | 1995-03-08 | 1996-05-07 | Century; Theodore J. | Powder dispenser |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
ZA967182B (en) | 1995-08-24 | 1998-05-25 | Magainin Pharma | Asthma associated factors as targets for treating atopic allergies including asthma and related disorders. |
US5817750A (en) | 1995-08-28 | 1998-10-06 | La Jolla Cancer Research Foundation | Structural mimics of RGD-binding sites |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
PL327616A1 (en) | 1996-01-03 | 1998-12-21 | Glaxo Group Ltd | Inhaler |
US5817457A (en) | 1996-02-07 | 1998-10-06 | Ma Bioservices, Inc. | Methods and kits for detecting viral reverse transcriptase activity in a sample using an acidic pH or an elevated temperature |
DE69736812T2 (de) | 1996-11-27 | 2007-08-09 | Bristol-Myers Squibb Pharma Co. | Neue integrin rezeptor antagonisten |
US5863769A (en) * | 1997-01-28 | 1999-01-26 | Smithkline Beecham Corporation | DNA encoding interleukin-1 receptor antagonist (IL-1raβ) |
US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
EP1491632A3 (en) | 1997-03-12 | 2006-01-04 | Smithkline Beecham Corporation | Anti-alphavbeta3 humanized monoclonal antibodies |
US5968741A (en) | 1997-04-11 | 1999-10-19 | Cedars-Sinai Medical Center | Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis |
CA2284726A1 (en) | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
US6171787B1 (en) | 1997-06-26 | 2001-01-09 | Abbott Laboratories | Member of the TNF family useful for treatment and diagnosis of disease |
US6096707A (en) | 1997-07-11 | 2000-08-01 | Biotie Therapies Ltd. | Integrin binding peptide and use thereof |
US6016800A (en) | 1997-10-24 | 2000-01-25 | Century; Theodore J. | Intrapulmonary aerosolizer |
WO1999027086A1 (en) * | 1997-11-25 | 1999-06-03 | Brax Group Limited | Chimeric antisense oligonucleotides against tnf-alpha and their uses |
AU1523199A (en) | 1997-11-26 | 1999-06-15 | Du Pont Pharmaceuticals Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as alphavbeta3 antagonists |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
EP1067940A4 (en) | 1998-03-03 | 2003-01-02 | Genaera Corp | FACTORS ASSOCIATED WITH ASTHMA AS TARGETS FOR THE TREATMENT OF ATOPIC ALLERGIES INCLUDING ASTHMA AND RELATED DISORDERS |
US6541623B1 (en) * | 1998-04-03 | 2003-04-01 | Hyseq, Inc. | Interleukin—1 receptor antagonist and uses thereof |
US6294655B1 (en) * | 1998-04-03 | 2001-09-25 | Hyseq, Inc. | Anti-interleukin-1 receptor antagonist antibodies and uses thereof |
EP1105389A4 (en) | 1998-08-13 | 2001-10-17 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
US6160099A (en) | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
US6114517A (en) | 1998-12-10 | 2000-09-05 | Isis Pharmaceuticals Inc. | Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules |
US6982089B2 (en) * | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
CA2330022A1 (en) * | 1999-04-06 | 2000-10-26 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion |
AU5282600A (en) * | 1999-05-20 | 2000-12-12 | Hyseq, Inc. | Interleukin-1 hy2 materials and methods |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
US20020068279A1 (en) * | 1999-12-06 | 2002-06-06 | Curagen Corporation | Novel Proteins and nucleic acids encoding the same |
ATE355836T1 (de) | 2000-01-31 | 2007-03-15 | Genaera Corp | Inhibitoren der mucin-synthese |
JP4194364B2 (ja) | 2000-10-16 | 2008-12-10 | デューク・ユニバーシティ | 嚢胞性繊維症におけるエアロゾル化されたs−ニトロソグルタチオンの治療的使用 |
AU2440802A (en) * | 2000-10-18 | 2002-04-29 | Massachusetts Inst Technology | Methods and products related to pulmonary delivery of polysaccharides |
US20020156009A1 (en) * | 2000-11-02 | 2002-10-24 | Dennis Ballinger | Novel interleukin - 1 Hy2 materials and methods |
US20020128179A1 (en) * | 2000-12-01 | 2002-09-12 | Tacon William C. | Shaped microparticles for pulmonary drug delivery |
EP1409536A2 (en) * | 2001-02-12 | 2004-04-21 | Curagen Corporation | Human proteins and nucleic acids encoding same |
EP1372720A4 (en) | 2001-03-02 | 2006-07-26 | Medimmune Inc | PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3 |
WO2002085308A2 (en) * | 2001-04-24 | 2002-10-31 | Epigenesis Pharmaceuticals, Inc. | Antisense and anti-inflammatory based compositions to treat respiratory disorders |
AUPR527801A0 (en) * | 2001-05-25 | 2001-06-21 | University Of Sydney, The | Animal husbandry iii |
EP1416957A4 (en) * | 2001-07-25 | 2006-08-02 | Nuvelo Inc | TREATMENT OF IMMUNE DISEASES AND B-CELL DISEASES |
AU2002359495A1 (en) | 2001-11-30 | 2003-06-17 | Centocor, Inc. | Anti-tnf antibodies, compositions, methods and uses |
US20040009149A1 (en) | 2002-02-27 | 2004-01-15 | Altman John D. | Multimeric binding complexes |
JP4133017B2 (ja) | 2002-06-20 | 2008-08-13 | 株式会社資生堂 | 毛髪処理用組成物 |
US7572770B2 (en) | 2002-06-27 | 2009-08-11 | University Of Zurich | Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
GB0300427D0 (en) * | 2003-01-09 | 2003-02-05 | Univ Strathclyde | Pharmaceutical composition |
WO2004098596A1 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising roflumilast and il-1 trap |
US20050186175A1 (en) * | 2004-02-20 | 2005-08-25 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on benzilic acid esters and soluble TNF receptor fusion proteins |
US7507745B2 (en) * | 2004-02-20 | 2009-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions based on fluorenecarboxylic acid esters and soluble TNF receptor fusion proteins |
BRPI0518622A2 (pt) * | 2004-12-02 | 2008-12-02 | Domantis Ltd | usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento |
GB0426609D0 (en) | 2004-12-03 | 2005-01-05 | Ic Innovations Ltd | Analysis |
US20090215868A1 (en) | 2005-01-13 | 2009-08-27 | Anges Mg, Inc. | Therapeutic Medicament for Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, and Pulmonary Hypertension |
SI2163562T1 (sl) * | 2005-06-21 | 2014-01-31 | Xoma (Us) Llc | IL-1 beta vezavna protitelesa in njihovi fragmenti |
US20070005651A1 (en) * | 2005-07-01 | 2007-01-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Restoring modified assets |
TW200745003A (en) * | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
PE20070823A1 (es) * | 2005-11-15 | 2007-08-09 | Glaxo Group Ltd | Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona |
CN101466734A (zh) * | 2005-12-01 | 2009-06-24 | 杜门蒂斯有限公司 | 与白细胞介素-1受体1型结合的竞争性域抗体形式 |
ATE439834T1 (de) * | 2005-12-21 | 2009-09-15 | Meda Pharma Gmbh & Co Kg | Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten |
US7504106B2 (en) * | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
WO2008008373A2 (en) * | 2006-07-11 | 2008-01-17 | Arubor Corp | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
CA3177366A1 (en) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
EP2475383A4 (en) * | 2009-09-06 | 2013-07-17 | Protab Ltd | FOR THE PEPTIDE PRODUCED FROM HSP65 6 SPECIFIC HUMANIZED ANTIBODIES AND USES THEREOF |
-
2007
- 2007-08-10 CA CA3177366A patent/CA3177366A1/en active Pending
- 2007-08-10 WO PCT/US2007/017800 patent/WO2008021237A1/en active Application Filing
- 2007-08-10 EP EP07836707.5A patent/EP2068889B1/en active Active
- 2007-08-10 JP JP2009523863A patent/JP2010500360A/ja active Pending
- 2007-08-10 HU HUE07836707A patent/HUE048024T2/hu unknown
- 2007-08-10 PL PL07836707T patent/PL2068889T3/pl unknown
- 2007-08-10 CA CA002660519A patent/CA2660519A1/en active Pending
- 2007-08-10 US US12/377,027 patent/US8940683B2/en active Active
- 2007-08-10 AU AU2007284690A patent/AU2007284690A1/en not_active Abandoned
- 2007-08-10 ES ES07836707T patent/ES2766770T3/es active Active
- 2007-08-10 PT PT78367075T patent/PT2068889T/pt unknown
- 2007-08-10 EP EP19204691.0A patent/EP3669878A1/en active Pending
- 2007-08-10 LT LTEP07836707.5T patent/LT2068889T/lt unknown
- 2007-08-10 SI SI200732142T patent/SI2068889T1/sl unknown
- 2007-08-10 DK DK07836707.5T patent/DK2068889T3/da active
-
2015
- 2015-01-26 US US14/605,545 patent/US10550389B2/en active Active
-
2019
- 2019-12-16 US US16/714,948 patent/US11091763B2/en active Active
-
2020
- 2020-01-20 CY CY20201100044T patent/CY1122533T1/el unknown
-
2021
- 2021-07-02 US US17/366,835 patent/US11718853B2/en active Active
-
2023
- 2023-06-07 US US18/330,588 patent/US20240084306A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8940683B2 (en) | 2015-01-27 |
LT2068889T (lt) | 2020-02-10 |
AU2007284690A1 (en) | 2008-02-21 |
JP2010500360A (ja) | 2010-01-07 |
EP2068889A1 (en) | 2009-06-17 |
WO2008021237A1 (en) | 2008-02-21 |
US20210395748A1 (en) | 2021-12-23 |
US20200362351A1 (en) | 2020-11-19 |
US10550389B2 (en) | 2020-02-04 |
PT2068889T (pt) | 2020-01-30 |
US11091763B2 (en) | 2021-08-17 |
US20150232855A1 (en) | 2015-08-20 |
EP3669878A1 (en) | 2020-06-24 |
US20100209357A1 (en) | 2010-08-19 |
ES2766770T3 (es) | 2020-06-15 |
HUE048024T2 (hu) | 2020-05-28 |
US11718853B2 (en) | 2023-08-08 |
CA2660519A1 (en) | 2008-02-21 |
DK2068889T3 (da) | 2020-02-03 |
PL2068889T3 (pl) | 2020-06-29 |
EP2068889A4 (en) | 2012-07-11 |
EP2068889B1 (en) | 2019-10-23 |
CA3177366A1 (en) | 2008-02-21 |
SI2068889T1 (sl) | 2020-03-31 |
US20240084306A1 (en) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122533T1 (el) | Ανακινρα για χρηση στην αντιμετωπιση συνδρομου αποφρακτικης βρογχιολιτιδας | |
ATE330589T1 (de) | Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege | |
EA200800905A1 (ru) | Агенты, связывающиеся с мишенью в легочной ткани, для лечения респираторных заболеваний | |
CY1121853T1 (el) | Συνδυαστικη θεραπεια για την αγωγη του διαβητη | |
DE60216588D1 (de) | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen | |
RS52940B (en) | PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS | |
DE602005026007D1 (de) | Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd) | |
CY1115940T1 (el) | Παραγωγα υποκατεστημενου φαινυλαλκανοϊκου οξεος και η χρηση τους για τη θεραπευτικη αντιμετωπιση αναπνευστικων ασθενειων | |
EA200702387A1 (ru) | Имидазохинолины в качестве ингибиторов липидкиназы | |
BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
EA200801165A1 (ru) | Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона | |
NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
CY1108421T1 (el) | Η χρηση σκευασματων μελοξικαμης στην κτηνιατρικη | |
NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
ATE410163T1 (de) | Verfahren zur behandlung und diagnose von atemstörungen im schlaf mit zonisamid und mittel zur durchführung des verfahrens | |
NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
MY145329A (en) | Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423) | |
MXPA05009629A (es) | Composiciones que contienen trospio. | |
EA201201395A1 (ru) | Кнопочное устройство мундштука ингалятора сухого порошка | |
RU2013157398A (ru) | Композиция | |
CN108366981B (zh) | 用于治疗与间质性肺病相关的咳嗽的甲磺司特 | |
UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
BR112012020377A2 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
EA200701077A1 (ru) | Применение конъюгатов липидов при лечении заболеваний |